{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:57:04Z","timestamp":1790758624265,"version":"4.1.0"},"reference-count":108,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KO1CA218305"],"award-info":[{"award-number":["KO1CA218305"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Ovarian cancer is the deadliest gynecological disease among U.S. women. Poor 5-year survival rates (&lt;30%) are due to presentation of most women at diagnosis with advanced stage disease with widely disseminated intraperitoneal metastasis. However, when diagnosed before metastatic propagation the overall 5-year survival rate is &gt;90%. Metastasizing tumor cells grow rapidly and aggressively attach to the mesothelium of all organs within the peritoneal cavity, including the parietal peritoneum and the omentum, producing secondary lesions. In this review, the involvement of mesothelin (MSLN) in the tumor microenvironment is discussed. MSLN, a 40kDa glycoprotein that is overexpressed in many cancers including ovarian and mesotheliomas is suggested to play a role in cell survival, proliferation, tumor progression, and adherence. However, the biological function of MSLN is not fully understood as MSLN knockout mice do not present with an abnormal phenotype. Conversely, MSLN has been shown to bind to the ovarian cancer antigen, CA-125, and thought to play a role in the peritoneal diffusion of ovarian tumor cells. Although the cancer-specific expression of MSLN makes it a potential therapeutic target, more studies are needed to validate the role of MSLN in tumor metastasis.<\/jats:p>","DOI":"10.3390\/cancers10090277","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T11:12:42Z","timestamp":1534849962000},"page":"277","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment"],"prefix":"10.3390","volume":"10","author":[{"given":"Tyvette S.","family":"Hilliard","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46617, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Peres, L.C., Cushing-Haugen, K.L., Kobel, M., Harris, H.R., Berchuck, A., Rossing, M.A., Schildkraut, J.M., and Doherty, J.A. (2018). Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl. Cancer Inst.","DOI":"10.1093\/jnci\/djy071"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00404-016-4035-8","article-title":"The new who classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications","volume":"293","author":"Fotopoulou","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_4","first-page":"255","article-title":"Ovarian surface epithelium: Biology, endocrinology, and pathology","volume":"22","author":"Auersperg","year":"2001","journal-title":"Endocr. Rev."},{"key":"ref_5","first-page":"32","article-title":"Ovarian epithelial cancer: Etiology and pathogenesis","volume":"10","author":"Choi","year":"2008","journal-title":"Biowave"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2741\/S401","article-title":"The origin of ovarian cancers\u2013hypotheses and controversies","volume":"5","author":"Auersperg","year":"2013","journal-title":"Front. Biosci. (Sch. Ed.)"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","article-title":"2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer","volume":"133","author":"Mutch","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/jnci\/85.18.1513","article-title":"Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer","volume":"85","author":"Kohler","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","article-title":"Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation","volume":"29","author":"Singer","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","first-page":"2128","article-title":"P53 mutation is a common genetic event in ovarian carcinoma","volume":"53","author":"Milner","year":"1993","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of brca1 and brca2 among ashkenazi jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of embrace","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer","volume":"7","author":"Tan","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2003.12.034","article-title":"Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers","volume":"93","author":"Burleson","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10585-004-5768-5","article-title":"Ovarian carcinoma spheroids disaggregate on type i collagen and invade live human mesothelial cell monolayers","volume":"21","author":"Burleson","year":"2004","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1023791229361","article-title":"Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread","volume":"22","author":"Carmignani","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1148\/radiology.169.3.3186993","article-title":"Peritoneal implants from ovarian tumors: Ct findings","volume":"169","author":"Buy","year":"1988","journal-title":"Radiology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: Building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: Rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","article-title":"New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination","volume":"175","author":"Coffman","year":"2016","journal-title":"Transl. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1148\/radiology.163.3.3575702","article-title":"The peritoneal ligaments and mesenteries: Pathways of intraabdominal spread of disease","volume":"163","author":"Meyers","year":"1987","journal-title":"Radiology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0009-9260(99)90018-1","article-title":"Imaging of peritoneal and mesenteric disease: Key concepts for the clinical radiologist","volume":"54","author":"Coakley","year":"1999","journal-title":"Clin. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.addr.2014.07.003","article-title":"Three-dimensional modeling of ovarian cancer","volume":"79\u201380","author":"White","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","article-title":"Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma","volume":"96","author":"Scholler","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000064032","article-title":"The ca 125 gene: A newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure","volume":"23","author":"Beard","year":"2002","journal-title":"Tumour Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the ca125 ovarian cancer antigen: Identification as a new mucin, muc16","volume":"276","author":"Yin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1757-2215-3-8","article-title":"The detection, treatment, and biology of epithelial ovarian cancer","volume":"3","author":"Gubbels","year":"2010","journal-title":"J. Ovarian Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ijc.10250","article-title":"Ovarian cancer antigen ca125 is encoded by the muc16 mucin gene","volume":"98","author":"Yin","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ygyno.2005.07.030","article-title":"Potent suppression of natural killer cell response mediated by the ovarian tumor marker ca125","volume":"99","author":"Patankar","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tibs.2009.10.003","article-title":"Mucin-interacting proteins: From function to therapeutics","volume":"35","author":"Senapati","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ejca.2011.07.004","article-title":"Ca125 (muc16) gene silencing suppresses growth properties of ovarian and breast cancer cells","volume":"48","author":"Reinartz","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.humpath.2012.01.005","article-title":"Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon","volume":"43","author":"Streppel","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1349-7006.2012.02214.x","article-title":"Coexpression of muc16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma","volume":"103","author":"Shimizu","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/s10434-006-9192-8","article-title":"Circulating ca125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","article-title":"Cellular and molecular processes in ovarian cancer metastasis","volume":"309","author":"Yeung","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1172\/JCI74778","article-title":"Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion","volume":"124","author":"Kenny","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","article-title":"The histophysiology and pathophysiology of the peritoneum","volume":"49","author":"Nieuwland","year":"2017","journal-title":"Tissue Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/dc.2840100313","article-title":"Immunocytochemical typification of mesothelial cells in effusions: In vivo and in vitro models","volume":"10","year":"1994","journal-title":"Diagn. Cytopathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1357-2725(03)00242-5","article-title":"The mesothelial cell","volume":"36","author":"Mutsaers","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_46","first-page":"157","article-title":"Ultrahistochemical demonstration of saccharide components of complex carbohydrates at the alveolar cell surface and at the mesothelial cell surface of the pleura visceralis of mice by means of concanavalin A","volume":"8","author":"Roth","year":"1973","journal-title":"Exp. Pathol. (Jena)"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"180594","DOI":"10.1155\/2011\/180594","article-title":"Pathophysiology of the peritoneal membrane during peritoneal dialysis: The role of hyaluronan","volume":"2011","author":"Yung","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/0008-5472.CAN-05-1292","article-title":"Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells","volume":"66","author":"Ren","year":"2006","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2014.02.034","article-title":"Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma","volume":"133","author":"Du","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa020809","article-title":"Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells","volume":"348","author":"Selgas","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/path.4281","article-title":"Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis","volume":"231","author":"Sandoval","year":"2013","journal-title":"J. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/path.4889","article-title":"Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer","volume":"242","author":"Barcena","year":"2017","journal-title":"J. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, k1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: A new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/stem.5530140708","article-title":"Characterization, molecular cloning and expression of megakaryocyte potentiating factor","volume":"14","author":"Yamaguchi","year":"1996","journal-title":"Stem Cells"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Schwab, M. (2011). Mesothelin. Encyclopedia of Cancer, Springer.","DOI":"10.1007\/978-3-642-16483-5"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Muminova, Z.E., Strong, T.V., and Shaw, D.R. (2004). Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer, 4.","DOI":"10.1186\/1471-2407-4-19"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1055-9965.EPI-05-0334","article-title":"Mesothelin variant 1 is released from tumor cells as a diagnostic marker","volume":"15","author":"Hellstrom","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sathyanarayana, B.K., Hahn, Y., Patankar, M.S., Pastan, I., and Lee, B. (2009). Mesothelin, stereocilin, and otoancorin are predicted to have superhelical structures with arm-type repeats. BMC Struct. Biol., 9.","DOI":"10.1186\/1472-6807-9-1"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1158\/0008-5472.CAN-07-0474","article-title":"High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent mcat motif","volume":"67","author":"Hucl","year":"2007","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1074\/jbc.M110.193458","article-title":"Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers","volume":"286","author":"Ren","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing mmp-7 through Mapk\/Erk and Jnk pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-05-1397","article-title":"Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma","volume":"12","author":"Yen","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Wang, K., Bodempudi, V., Liu, Z., Borrego-Diaz, E., Yamoutpoor, F., Meyer, A., Woo, R.A., Pan, W., Dudek, A.Z., and Olyaee, M.S. (2012). Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033214"},{"key":"ref_68","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (sage)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen ca125\/muc16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"Li","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","article-title":"Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin e via activation of signal transducer and activator of transcription protein 3","volume":"6","author":"Bharadwaj","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine il-6\/sil-6r trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to tnf-alpha-induced apoptosis through akt\/pi3k\/nf-kappab activation and il-6\/mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20082196","article-title":"Mesothelin inhibits paclitaxel-induced apoptosis through the pi3k pathway","volume":"424","author":"Chang","year":"2009","journal-title":"Biochem. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","article-title":"Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells","volume":"6","author":"Uehara","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-muc16 binding is a high affinity, n-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"28619","DOI":"10.1074\/jbc.M302741200","article-title":"Characterization of the oligosaccharides associated with the human ovarian tumor marker ca125","volume":"278","author":"Easton","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for ca125\/muc16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2006.03.029","article-title":"Development of a ca125-mesothelin cell adhesion assay as a screening tool for biologics discovery","volume":"247","author":"Scholler","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1515\/hsz-2014-0155","article-title":"Membrane-type i matrix metalloproteinase-dependent ectodomain shedding of mucin16\/ca-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium","volume":"395","author":"Bruney","year":"2014","journal-title":"Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ijgc-00009577-200511001-00015","article-title":"New tumor markers: Ca125 and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hilliard, T., Iwamoto, K., Loughran, E., Liu, Y., Yang, J., Asem, M., Tarwater, L., Klymenko, Y., Johnson, J., and Shi, Z. (2018). Mesothelin expression increases ovarian cancer metastasis in the peritoneal microenvironment. Cancer Lett., in press.","DOI":"10.3390\/cancers10090277"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"114","DOI":"10.18632\/oncotarget.445","article-title":"Modulating mesothelin shedding to improve therapy","volume":"3","author":"Pastan","year":"2012","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1055-9965.EPI-06-0479","article-title":"Mesothelin is shed from tumor cells","volume":"15","author":"Ho","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_88","first-page":"4721","article-title":"Serum mesothelin in epithelial ovarian carcinoma: A new screening marker and prognostic factor","volume":"26","author":"Huang","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2004.07.039","article-title":"Combining ca 125 and smr serum markers for diagnosis and early detection of ovarian carcinoma","volume":"95","author":"McIntosh","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1158\/0008-5472.CAN-11-0466","article-title":"Cytotoxic activity of immunotoxin ss1p is modulated by tace-dependent mesothelin shedding","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Pham, T., Mero, P., and Booth, J.W. (2011). Dynamics of macrophage trogocytosis of rituximab-coated b cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0014498"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of erbb2 in jimt-1, a herceptin-resistant, muc4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1166\/jbn.2015.2063","article-title":"Anti-mesothelin nanobodies for both conventional and nanoparticle-based biomedical applications","volume":"11","author":"Prantner","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1021\/acs.molpharmaceut.7b00789","article-title":"Molecular imaging of mesothelin-expressing ovarian cancer with a human and mouse cross-reactive nanobody","volume":"15","author":"Prantner","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1535-7163.MCT-16-0449","article-title":"Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative 89zr-immunopet","volume":"16","author":"Ogasawara","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Sirois, A.R., Deny, D.A., Baierl, S.R., George, K.S., and Moore, S.J. (2018). Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197029"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1148\/radiol.12111504","article-title":"Use of (64)cu-labeled fibronectin domain with egfr-overexpressing tumor xenograft: Molecular imaging","volume":"263","author":"Hackel","year":"2012","journal-title":"Radiology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.7150\/thno.15169","article-title":"Ultrasound molecular imaging of the breast cancer neovasculature using engineered fibronectin scaffold ligands: A novel class of targeted contrast ultrasound agent","volume":"6","author":"Wilson","year":"2016","journal-title":"Theranostics"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Park, S.H., Park, S., Kim, D.Y., Pyo, A., Kimura, R.H., Sathirachinda, A., Choy, H.E., Min, J.J., Gambhir, S.S., and Hong, Y. (2015). Isolation and characterization of a monobody with a fibronectin domain iii scaffold that specifically binds epha2. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132976"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00726-010-0503-9","article-title":"Protein scaffold-based molecular probes for cancer molecular imaging","volume":"41","author":"Miao","year":"2011","journal-title":"Amino Acids"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.2014-0358","article-title":"Advances in anticancer immunotoxin therapy","volume":"20","author":"Alewine","year":"2015","journal-title":"Oncologist"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase i trial of continuous infusion anti-mesothelin recombinant immunotoxin ss1p","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase i study of ss1p, a recombinant anti-mesothelin immunotoxin given as a bolus i.V. Infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin-ca-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody morab-009: Implications for cancer therapy","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase i clinical trial of the chimeric anti-mesothelin monoclonal antibody morab-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated listeria vaccine (anz-100) and a live-attenuated listeria vaccine expressing mesothelin (crs-207) for advanced cancers: Phase i studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mrna-engineered t cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/9\/277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:19:55Z","timestamp":1760195995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/9\/277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":108,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["cancers10090277"],"URL":"https:\/\/doi.org\/10.3390\/cancers10090277","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]}}}